Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of LVRNA021 COVID-19 Vaccine in Chinese Adults
NCT05547243Phase 2Unknown
- Sponsor
- AIM Vaccine Co., Ltd.
- Start
- Sep 2022
- Primary completion
- Dec 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of LVRNA021 in coronavirus disease 2019 (COVID-19), sponsored by AIM Vaccine Co., Ltd.. Status: unknown.
02
Drugs
LVRNA021
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05547243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05547243.